Alnylam is making a series of changes to a closely-watched study of its ATTR amyloidosis drug vutrisiran that will delay the Phase III readout from early this year to late June or early July.
The biotech said Thursday it’s adding a subgroup of patients receiving only vutrisiran to its primary analysis. Now, the primary endpoint of the HELIOS-B study will measure rates of death and major cardiovascular events in both the overall study population and a subgroup that is on only vutrisiran.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.